Cargando…

Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes

Treatment for myelodysplastic syndromes (MDS) remains insufficient due to clonal heterogeneity and lack of effective clinical therapies. Dysregulation of apoptosis is observed across MDS subtypes regardless of mutations and represents an attractive therapeutic opportunity. Venetoclax (VEN), a select...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fischer, Melissa A., Song, Yuanbin, Arrate, Maria P., Gbyli, Rana, Villaume, Matthew T., Smith, Brianna N., Childress, Merrida A., Stricker, Thomas P., Halene, Stephanie, Savona, Michael R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Article - Myelodysplastic Syndromes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890032/ https://www.ncbi.nlm.nih.gov/pubmed/35979721 http://dx.doi.org/10.3324/haematol.2022.280631

Ejemplares similares

Artificial intelligence to empower diagnosis of myelodysplastic syndromes by multiparametric flow cytometry
por: Clichet, Valentin, et al.
Publicado: (2023)

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine
por: Karantanos, Theodoros, et al.
Publicado: (2022)

High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes
por: Teichman, Jennifer, et al.
Publicado: (2022)

Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation
por: Muto, Tomoya, et al.
Publicado: (2023)

Role of iron chelation in improving survival: An integral part of current therapy for myelodysplastic syndromes
por: Taran, Sachi Jain, et al.
Publicado: (2015)

Routine clinical parameters and laboratory testing predict therapy-related myeloid neoplasms after treatment for breast cancer
por: Petrone, Giulia, et al.
Publicado: (2022)

Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms
por: Badar, Talha, et al.
Publicado: (2023)

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Savona, Michael R., et al.
Publicado: (2020)

Immunogenicity of Covid-19 Vaccination in Subjects with Myelodysplastic Syndromes
por: Vidler, Jennifer, et al.
Publicado: (2021)

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study
por: Garcia-Manero, Guillermo, et al.
Publicado: (2021)

Myelodysplastic Syndromes (MDS) & COVID-19: Clinical Experience from the US Epicenter of the Pandemic
por: Feld, Jonathan, et al.
Publicado: (2020)

COVID-19 Outcomes Among Participants in the NHLBI Myelodysplastic Syndromes (MDS) Natural History Study
por: Padron, Eric, et al.
Publicado: (2021)

Incidence and Burden of the Myelodysplastic Syndromes
por: Cogle, Christopher R.
Publicado: (2015)

Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes
por: Drusbosky, Leylah M., et al.
Publicado: (2017)

Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?
por: Bejar, Rafael
Publicado: (2015)

High-risk MDS after HMAs
por: Adès, Lionel
Publicado: (2019)

The impact of spliceosome mutations in MDS
por: Boultwood, Jacqueline, et al.
Publicado: (2019)

The role of innate immunity in MDS pathogenesis
por: Sallman, David A., et al.
Publicado: (2019)

Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study
por: Savona, Michael R., et al.
Publicado: (2021)

Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax
por: Jehangir, Waqas, et al.
Publicado: (2020)

Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia
por: Cojocari, Dan, et al.
Publicado: (2021)

Salivary Gland Stem Cells Age Prematurely in Primary Sjögren's Syndrome
por: Pringle, Sarah, et al.
Publicado: (2018)

TRPV6 compound heterozygous variants result in impaired placental calcium transport and severe undermineralization and dysplasia of the fetal skeleton
por: Burren, Christine P., et al.
Publicado: (2018)

Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren’s syndrome that show potential to predict and monitor clinical response
por: Hamkour, Safae, et al.
Publicado: (2023)

Deciphering the role of cDC2s in Sjögren’s syndrome: transcriptomic profile links altered antigen processes with IFN signature and autoimmunity
por: Lopes, Ana P, et al.
Publicado: (2023)

A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells
por: Zhao, Tianming, et al.
Publicado: (2023)

Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes
por: Sochacki, Andrew L, et al.
Publicado: (2016)

Proteogenomic analysis of the autoreactive B cell repertoire in blood and tissues of patients with Sjögren’s syndrome
por: Broeren, Mathijs G A, et al.
Publicado: (2022)

Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy
por: Bezzina, Oriana M., et al.
Publicado: (2017)

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation
por: Thus, Yvonne J., et al.
Publicado: (2022)

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
por: Yi, Xue, et al.
Publicado: (2022)

Weight change over five-year periods and number of components of the metabolic syndrome in a Dutch cohort
por: Bot, M., et al.
Publicado: (2010)

Short- and long-term effects of erythropoietin treatment on endothelial progenitor cell levels in patients with cardiorenal syndrome
por: Jie, Kim E, et al.
Publicado: (2010)

Syndrome in Question()
por: Orasmo, Cínthia Rosane, et al.
Publicado: (2014)

Syndrome in Question()
por: Meireles, Sheila Itamara Ferreira do Couto, et al.
Publicado: (2014)

Syndrome in question*
por: Wu, Yinhua, et al.
Publicado: (2014)

Do you know this syndrome?()
por: Frainer, Renata Hubner, et al.
Publicado: (2013)

Do you know this syndrome?
por: Gontijo, Gabriela Maria Abreu
Publicado: (2013)

Do you know this syndrome?*
por: Silveira, Laura Maria Andrade, et al.
Publicado: (2013)

Do you know this syndrome?
por: Kondo, Rogerio Nabor, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ht5g2onlscha1iq08fapo2tcsg